AstraZeneca plc (NYSE:AZN) – Research analysts at Jefferies Group boosted their FY2021 earnings per share estimates for shares of AstraZeneca in a research note issued to investors on Monday. Jefferies Group analyst J. Holford now anticipates that the company will earn $2.70 per share for the year, up from their previous estimate of $2.68.
Other analysts also recently issued reports about the company. BMO Capital Markets reiterated a “buy” rating and set a $38.00 price target on shares of AstraZeneca in a report on Tuesday, November 7th. Sanford C. Bernstein increased their price target on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Leerink Swann increased their price target on AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a report on Tuesday, February 6th. ValuEngine upgraded AstraZeneca from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 3rd. Finally, Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $36.26.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.86. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The firm had revenue of $5.78 billion during the quarter, compared to the consensus estimate of $5.49 billion. During the same period last year, the business posted $1.21 EPS. The business’s revenue was up 3.4% compared to the same quarter last year.
The company also recently announced a semiannual dividend, which will be paid on Monday, March 19th. Stockholders of record on Friday, February 16th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s dividend payout ratio is presently 57.81%.
Institutional investors and hedge funds have recently modified their holdings of the company. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of AstraZeneca in the 4th quarter valued at about $101,000. Valeo Financial Advisors LLC acquired a new stake in shares of AstraZeneca in the 3rd quarter valued at about $133,000. Delpha Capital Management LLC acquired a new position in AstraZeneca during the 4th quarter valued at about $152,000. Calton & Associates Inc. acquired a new position in AstraZeneca during the 4th quarter valued at about $181,000. Finally, Wealthcare Advisory Partners LLC acquired a new position in AstraZeneca during the 3rd quarter valued at about $184,000. Institutional investors own 14.91% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) Forecasted to Post FY2021 Earnings of $2.70 Per Share” was published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3228641/astrazeneca-plc-azn-forecasted-to-post-fy2021-earnings-of-2-70-per-share.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.